U251 MG/TMZ Cells
USUSD$1,200.00*
Products are shipped frozen on dry ice in cryotubes. Each cryotube typically contains 3 × 106 cells for adherent lines or 5 × 106 cells for suspension lines (refer to the batch CoA for details).
一般資訊
| 說明 | U251 MG/TMZ is a temozolomide-resistant derivative of the human glioblastoma cell line U251 MG. The parental U251 MG line was established from the malignant glioma of an adult patient and is widely used as a model of high-grade astrocytic tumors. U251 MG/TMZ cells are generated through stepwise, long-term exposure of parental U251 MG cells to increasing concentrations of temozolomide (TMZ), the standard alkylating chemotherapeutic agent used in glioblastoma treatment. This selection process results in a stable phenotype characterized by significantly reduced sensitivity to TMZ-induced cytotoxicity compared to the parental line. Mechanistically, TMZ resistance in U251 MG/TMZ cells is commonly associated with upregulation of O6-methylguanine-DNA methyltransferase (MGMT), enhanced DNA damage repair capacity, alterations in mismatch repair pathways, and activation of pro-survival signaling cascades. Resistant cells frequently exhibit reduced apoptosis following TMZ exposure, with decreased caspase activation and attenuated mitochondrial pathway engagement. Additional molecular adaptations may include dysregulation of PI3K/AKT, MAPK, NF-κB, or STAT3 signaling pathways, as well as altered expression of drug transporters and stemness-associated markers, depending on the selection protocol used. U251 MG/TMZ cells maintain adherent growth with astrocytic morphology similar to the parental line but demonstrate higher TMZ IC50 values and sustained proliferation under drug pressure. This model is widely used to investigate mechanisms of acquired chemoresistance, identify biomarkers predictive of therapeutic response, and evaluate novel combinatorial strategies aimed at overcoming TMZ resistance. As such, U251 MG/TMZ provides a clinically relevant in vitro platform for studying treatment failure and therapeutic vulnerability in glioblastoma. |
|---|---|
| 生物體 | Human |
| 組織 | Brain |
| 疾病 | Astrocytoma |
| 同義詞 | U-251MG, U-251-MG, U-251_MG, U251-MG, U251MG, U-251, U251, U251n, U251N, 251 MG, 251MG |
特徵
| 年齡 | 75 years |
|---|---|
| 性別 | Male |
| 族裔 | Caucasian |
| 形態學 | Epithelial-like |
| 生長特性 | Adherent |
監管數據
| 引用 | U251 MG/TMZ (Cytion catalog number 305884) |
|---|---|
| 生物安全等級 | 1 |
| NCBI_TaxID | 9606 |
生物分子資料
| 突變譜 | TMZ-resistant |
|---|
處理方式
| 培養基 | DMEM, w: 4.5 g/L Glucose, w: 4 mM L-Glutamine, w: 3.7 g/L NaHCO3, w: 1.0 mM Sodium pyruvate (Cytion article number 820300a) |
|---|---|
| 營養補充品 | Supplement the medium with 10% FBS and 50 µM Temozolomid (TMZ) |
| 解離試劑 | Accutase |
| 冷凍培養基 | As a cryopreservation medium, we use complete growth medium + 10% DMSO for adequate post-thaw viability. |
| 細胞解凍與培養 |
|
| 培養環境 | 37°C, 5% CO2, humidified atmosphere. |
| 運送條款 | Cryopreserved cell lines are shipped on dry ice in validated, insulated packaging with sufficient refrigerant to maintain approximately −78 °C throughout transit. On receipt, inspect the container immediately and transfer vials without delay to appropriate storage. |
| 儲存條件 | For long-term preservation, place vials in vapor-phase liquid nitrogen at about −150 to −196 °C. Storage at −80 °C is acceptable only as a short interim step before transfer to liquid nitrogen. |
品質控制與分子分析
分析證明書 (CoA)
| 批次編號 | 證書類型 | 日期 | 型號 |
|---|---|---|---|
| 305884-241125 | 分析證明書 | 15. Jan. 2026 | 305884 |